T2 Biosystems Announces FDA 510(K) Submission To Expand The Pathogen Detection On Its FDA-Cleared T2Bacteria Panel To Include Detection Of Acinetobacter Baumannii
Portfolio Pulse from Benzinga Newsdesk
T2 Biosystems has submitted an FDA 510(K) application to expand the pathogen detection on its FDA-cleared T2Bacteria Panel to include detection of Acinetobacter Baumannii.
October 12, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
T2 Biosystems' FDA 510(K) submission could potentially expand the capabilities of its T2Bacteria Panel, potentially increasing its market appeal.
The FDA 510(K) submission by T2 Biosystems is a significant step towards expanding the capabilities of its T2Bacteria Panel. If approved, it could increase the product's market appeal by allowing it to detect more pathogens, potentially leading to increased sales and a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100